enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage, non-viral genetic medicines company, has released its financial results for the second quarter ended April 30, 2025. The company reported a net loss attributable to common shareholders of approximately $25.8 million, or $0.51 per share. This reflects an increase from the net loss of about $15.0 million, or $0.38 per share, recorded in the same period the previous year. The increase in net loss is mainly due to higher operating expenses, partially offset by net interest income. The company remains on track for its Biologics License Application $(BLA.AU)$ filing for mid-2026, with additional preliminary data from the ongoing LEGEND study anticipated in the second half of 2025. enGene also completed the European Medicines Agency $(EMA)$ Scientific Advice process, indicating that the data could support a Conditional Marketing Authorization Application for detalimogene in BCG-unresponsive NMIBC with CIS, assuming a positive benefit-risk ratio. Additionally, enGene announced the appointment of Amy Pott as Chief Global Commercialization Officer in May 2025, highlighting a strategic move towards strengthening its commercialization efforts. The company holds cash and marketable securities amounting to $251.5 million, expected to sustain operations into 2027.